Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Rex

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Nature Reviews. Drug Discovery|November 16, 2013
The value of single-pathogen antibacterial agentsBrad Spellberg, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2002
All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular cathetersThomas J Walsh, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 2, 2002
Has antifungal susceptibility testing come of age?John H Rex, Michael A Pfaller
Current Opinion in Pharmacology|December 17, 2017
Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogensSujata M Bhavnani, John H Rex
Antimicrobial Agents and Chemotherapy|August 17, 2002
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolatesSevtap Arikan, Victor Paetznick, John H Rex
Nature Reviews. Drug Discovery|February 2, 2012
The critical impact of time discounting on economic incentives to overcome the antibiotic market failureBrad Spellberg, Priya Sharma, John H Rex
Journal of Clinical Microbiology|May 8, 2004
Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolatesVishnu Chaturvedi, Rama Ramani, John H Rex
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsJohn F Mohr, Audrey Wanger, John H Rex
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causalityWilliam Hope, George L Drusano, John H Rex
Open Forum Infectious Diseases|July 20, 2022
The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare PathogensAaron Dane, John H Rex, Paul Newell, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Nature Reviews. Drug Discovery|November 16, 2013
The value of single-pathogen antibacterial agentsBrad Spellberg, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2002
All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular cathetersThomas J Walsh, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 2, 2002
Has antifungal susceptibility testing come of age?John H Rex, Michael A Pfaller
Current Opinion in Pharmacology|December 17, 2017
Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogensSujata M Bhavnani, John H Rex
Antimicrobial Agents and Chemotherapy|August 17, 2002
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolatesSevtap Arikan, Victor Paetznick, John H Rex
Nature Reviews. Drug Discovery|February 2, 2012
The critical impact of time discounting on economic incentives to overcome the antibiotic market failureBrad Spellberg, Priya Sharma, John H Rex
Journal of Clinical Microbiology|May 8, 2004
Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolatesVishnu Chaturvedi, Rama Ramani, John H Rex
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsJohn F Mohr, Audrey Wanger, John H Rex
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causalityWilliam Hope, George L Drusano, John H Rex
Open Forum Infectious Diseases|July 20, 2022
The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare PathogensAaron Dane, John H Rex, Paul Newell, et al.
Pageof 10